X4 Pharmaceuticals (XFOR) Other Working Capital Changes (2025 - 2026)

X4 Pharmaceuticals (XFOR) has reported Other Working Capital Changes for 10 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 1357.08% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2026 stood at -$1.6 million (down 672.26% YoY), and the FY2025 full-year result was -$4.2 million, down 521.96% from the prior year.
• Other Working Capital Changes grew to $3.0 million in Q2 2026 per XFOR's latest filing, from -$778000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $1.8 million in Q1 2025 and bottomed at -$296000.0 in Q4 2025.
• Historically, Other Working Capital Changes has averaged -$39555.6 across 5 years, with a median of -$90500.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Other Working Capital Changes slumped 758.75% in 2025, then surged 1357.08% in 2026.
• Over 5 years, Other Working Capital Changes stood at $768000.0 in 2022, then surged by 138.15% to $1.8 million in 2023, then slumped by 71.9% to $514000.0 in 2024, then plunged by 758.75% to -$3.4 million in 2025, then surged by 189.1% to $3.0 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $3.0 million, -$778000.0, and -$3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.